CLINICAL TRIAL

Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2026-05-27
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

NYU Langone Health

Watch author

Derived topics and classifications

psilocybin Brain Imaging Emotional Processing Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use DisorderClinicalTrials.gov · 2026-08-12 The Effects of Psilocybin on Social ConnectednessClinicalTrials.gov · 2026-07-09 Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot StudyClinicalTrials.gov · 2026-06-23 The Acute Effects of Psilocybin on Cognition, Memory, and Brain FunctionClinicalTrials.gov · 2026-06-15 A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive DisorderClinicalTrials.gov · 2026-05-06 Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional HealthClinicalTrials.gov · 2026-03-11 The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.ClinicalTrials.gov · 2026-02-25 Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy in Major DepressionClinicalTrials.gov · 2022-04-29